Page last updated: 2024-08-21

dronabinol and Acute Lymphoid Leukemia

dronabinol has been researched along with Acute Lymphoid Leukemia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Akmut, F; Illing, B; Kampa-Schittenhelm, KM; Kanz, L; Salih, HR; Salitzky, O; Schittenhelm, MM1
Kaminski, NE; Rao, GK1
Abrahamov, A; Mechoulam, R1
Fisher, M; Grant, S; Lombard, C; Martin, BR; McKallip, RJ; Nagarkatti, M; Nagarkatti, PS; Ryu, S1

Other Studies

4 other study(ies) available for dronabinol and Acute Lymphoid Leukemia

ArticleYear
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns.
    BMC cancer, 2016, Jan-16, Volume: 16

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dronabinol; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2

2016
Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels.
    Journal of leukocyte biology, 2006, Volume: 79, Issue:1

    Topics: Analgesics, Non-Narcotic; Calcium; Calcium Signaling; Calcium-Transporting ATPases; Cell Line, Tumor; Dronabinol; Enzyme Inhibitors; Humans; Ion Channel Gating; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase C; Receptor, Cannabinoid, CB2; Ryanodine Receptor Calcium Release Channel; T-Lymphocytes; TRPC Cation Channels

2006
An efficient new cannabinoid antiemetic in pediatric oncology.
    Life sciences, 1995, Volume: 56, Issue:23-24

    Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Dronabinol; Female; Hodgkin Disease; Humans; Infant; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Wilms Tumor

1995
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
    Blood, 2002, Jul-15, Volume: 100, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cannabinoids; Cell Survival; Dose-Response Relationship, Drug; Dronabinol; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphoid; Ligands; Mice; Mice, Inbred C57BL; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Cannabinoid; Receptors, Drug; Survival Rate; Treatment Outcome; Tumor Cells, Cultured

2002